These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 19292067)

  • 21. Biodistribution and excretion of radiolabeled 40 kDa polyethylene glycol following intravenous administration in mice.
    Longley CB; Zhao H; Lozanguiez YL; Conover CD
    J Pharm Sci; 2013 Jul; 102(7):2362-70. PubMed ID: 23613432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat.
    Castell JV; Geiger T; Gross V; Andus T; Walter E; Hirano T; Kishimoto T; Heinrich PC
    Eur J Biochem; 1988 Nov; 177(2):357-61. PubMed ID: 3263918
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin.
    Yáñez JA; Forrest ML; Ohgami Y; Kwon GS; Davies NM
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):133-44. PubMed ID: 17393166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical safety studies with recombinant human interleukin 6 (rhIL-6) in the primate Callithrix jacchus (marmoset): comparison with studies in rats.
    Ryffel B; Weber M
    J Appl Toxicol; 1995; 15(1):19-26. PubMed ID: 7538156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of subcutaneous injection and intravenous infusion of recombinant human interleukin-12 and recombinant human interleukin-12 combined with hepatitis B surface antigen in cynomolgus monkeys.
    Li R; Deng F; Fu Y; Zhang Y; Wan H; Zhou D; Gu J; Xu J
    Pharmacology; 2010; 85(6):319-27. PubMed ID: 20516733
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates.
    Yang Z; Wang J; Lu Q; Xu J; Kobayashi Y; Takakura T; Takimoto A; Yoshioka T; Lian C; Chen C; Zhang D; Zhang Y; Li S; Sun X; Tan Y; Yagi S; Frenkel EP; Hoffman RM
    Cancer Res; 2004 Sep; 64(18):6673-8. PubMed ID: 15374983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
    Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous administration of recombinant glycosylated interleukin 6 in patients with cancer: pharmacokinetics, pharmacodynamics and immunomodulatory effects.
    Banks RE; Forbes MA; Patel PM; Storr M; Hallam S; Clarke D; Novick D; Ingham E; Bowmer C; Southgate J; Trejdosiewicz LK; Illingworth J; Perren TJ; Selby PJ
    Cytokine; 2000 Apr; 12(4):388-96. PubMed ID: 10805221
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Self-assembling nanocomposites for protein delivery: supramolecular interactions between PEG-cholane and rh-G-CSF.
    Salmaso S; Bersani S; Mastrotto F; Tonon G; Schrepfer R; Genovese S; Caliceti P
    J Control Release; 2012 Aug; 162(1):176-84. PubMed ID: 22727711
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Evaluation of Optimal PEGylation Strategies for Maximizing the Lymphatic Exposure and Antiviral Activity of Interferon after Subcutaneous Administration.
    Chan LJ; Feeney OM; Leong NJ; McLeod VM; Porter CJH; Williams CC; Kaminskas LM
    Biomacromolecules; 2017 Sep; 18(9):2866-2875. PubMed ID: 28731677
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of Polyethylene Glycol-Modified Canine Uricase Following Single and Multiple Intravenous Injections in Cynomolgus Monkeys.
    Li H; Huo J; Sun D; Jiang L; Hu C; Bai Y; Ma X; Zhang H; Shi X; Zhao Z; Zhou J; Lu Y; Zhang C
    Eur J Drug Metab Pharmacokinet; 2020 Aug; 45(4):445-451. PubMed ID: 32162270
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of PEG-hemoglobin SB1, a hemoglobin-based oxygen carrier, after its intravenous administration in beagle dogs.
    Kwon OS; Chung UT; Chung YB
    Arch Pharm Res; 2004 Feb; 27(2):259-64. PubMed ID: 15022731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lymphatic transport and catabolism of therapeutic proteins after subcutaneous administration to rats and dogs.
    Wang W; Chen N; Shen X; Cunningham P; Fauty S; Michel K; Wang B; Hong X; Adreani C; Nunes CN; Johnson CV; Yin KC; Groff M; Zou Y; Liu L; Hamuro L; Prueksaritanont T
    Drug Metab Dispos; 2012 May; 40(5):952-62. PubMed ID: 22328584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fate of interleukin-6 in the rat. Involvement of skin in its catabolism.
    Castell J; Klapproth J; Gross V; Walter E; Andus T; Snyers L; Content J; Heinrich PC
    Eur J Biochem; 1990 Apr; 189(1):113-8. PubMed ID: 2331992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of molecular weight and PEG chain length on the systemic pharmacokinetics of PEGylated poly l-lysine dendrimers.
    Kaminskas LM; Boyd BJ; Karellas P; Krippner GY; Lessene R; Kelly B; Porter CJ
    Mol Pharm; 2008; 5(3):449-63. PubMed ID: 18393438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats.
    Zhang S; Wang J; Pan J
    Drug Deliv; 2016 Nov; 23(9):3696-3703. PubMed ID: 27749105
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I study including pharmacokinetics of polyethylene glycol conjugated interleukin-2.
    Meyers FJ; Paradise C; Scudder SA; Goodman G; Konrad M
    Clin Pharmacol Ther; 1991 Mar; 49(3):307-13. PubMed ID: 2007324
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization, efficacy, pharmacokinetics, and biodistribution of 5kDa mPEG modified tetrameric canine uricase variant.
    Zhang C; Fan K; Luo H; Ma X; Liu R; Yang L; Hu C; Chen Z; Min Z; Wei D
    Int J Pharm; 2012 Jul; 430(1-2):307-17. PubMed ID: 22503989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical trial: single- and multiple-dose pharmacokinetics of polyethylene glycol (PEG-3350) in healthy young and elderly subjects.
    Pelham RW; Nix LC; Chavira RE; Cleveland MV; Stetson P
    Aliment Pharmacol Ther; 2008 Jul; 28(2):256-65. PubMed ID: 18462266
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Liposomal topotecan formulation with a low polyethylene glycol grafting density: pharmacokinetics and antitumour activity.
    Li C; Wang C; Yang H; Zhao X; Wei N; Cui J
    J Pharm Pharmacol; 2012 Mar; 64(3):372-82. PubMed ID: 22309269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.